Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

Company Overview

Petros Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for men’s health conditions. The company’s activities are primarily centered on treatments for erectile dysfunction and other conditions affecting male sexual health.

Petros’ lead commercial product is STENDRA (avanafil), a prescription phosphodiesterase type 5 inhibitor indicated for the treatment of erectile dysfunction in adult men. The company has also pursued regulatory and clinical development initiatives intended to expand access to STENDRA, including evaluating the potential for an over-the-counter version. Its development efforts have included additional therapies for men’s health, such as investigational treatments for Peyronie’s disease.

Petros primarily serves the U.S. pharmaceutical market and has focused on building a portfolio of branded and potentially consumer-accessible men’s health products. The company became a publicly traded business through a transaction involving Neurotrope, Inc. in 2020. Fady Boctor has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $0.0028 to $0.0037
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.02
• Volume: 271,578 shs
• Average Volume: 115,272 shs
• Market Capitalization: $99.71 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 5/15/2025
• Today: 10/13/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PTPI
• CIK: 1815903
• Web: www.petrospharma.com
• Phone: 973-242-0005
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.16 million
• Net Margins: N/A
• Pretax Margin: -117.50%
• Return on Equity: -78.22%
• Return on Assets: -23.50%

Debt

• Debt-to-Equity Ratio: 1.58
• Current Ratio: 0.85
• Quick Ratio: 0.74

Sales & Book Value

• Annual Sales: $5.11 million
• Price / Sales: 0.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 31,160,000
• Free Float: 9,932,000
• Market Cap: $99.71 thousand
• Optionable: Not Optionable
• Beta: 1.87